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Abstract
Background
Metamizole is used to treat pain in many parts of the world. Information on the safety profile
of metamizole is scarce; no conclusive summary of the literature exists.
Objective
To determine whether metamizole is clinically safe compared to placebo and
other analgesics.
Methods
We searched CENTRAL, MEDLINE, EMBASE, CINAHL, and several clinical trial registries.
We screened the reference lists of included trials and previous systematic reviews. We in-
cluded randomized controlled trials that compared the effects of metamizole, administered
to adults in any form and for any indication, to other analgesics or to placebo. Two authors
extracted data regarding trial design and size, indications for pain medication, patient char-
acteristics, treatment regimens, and methodological characteristics. Adverse events (AEs),
serious adverse events (SAEs), and dropouts were assessed. We conducted separate
meta-analyses for each metamizole comparator, using standard inverse-variance random
effects meta-analysis to pool the estimates across trials, reported as risk ratios (RRs). We
calculated the DerSimonian and Laird variance estimate T2 to measure heterogeneity be-
tween trials. The pre-specified primary end point was any AE during the trial period.
Results
Of the 696 potentially eligible trials, 79 trials including almost 4000 patients with short-term
metamizole use of less than two weeks met our inclusion criteria. Fewer AEs were reported
for metamizole compared to opioids, RR = 0.79 (confidence interval 0.79 to 0.96). We found
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no differences between metamizole and placebo, paracetamol and NSAIDs. Only a few
SAEs were reported, with no difference between metamizole and other analgesics. No
agranulocytosis or deaths were reported. Our results were limited by the mediocre overall
quality of the reports.
Conclusion
For short-term use in the hospital setting, metamizole seems to be a safe choice when com-
pared to other widely used analgesics. High-quality, adequately sized trials assessing the
intermediate- and long-term safety of metamizole are needed.
Introduction
Metamizole, or dipyrone, is a pyrazolone derivate whose structure is closely related to that of
amidopyrine. It was launched commercially as an analgesic and antipyretic by Hoechst AG in
1922 [1], and is commonly used to treat postoperative pain, colic pain, cancer pain and mi-
graine [2–4]. In many parts of the world, including most countries in the European Union and
Latin America, it is the most popular non-opioid first-line analgesic and is sometimes even
available over-the-counter. A few countries however, including the United States, the United
Kingdom, Sweden, and most recently India [5], have banned metamizole because health au-
thorities judged the risk of agranulocytosis to outweigh the benefits [6–8].
Although used for more than 90 years, the risks and harms of metamizole are not well docu-
mented, and information on adverse events related to metamizole is scarce. There are no large
randomized controlled trials or conclusive summaries of the existing literature [9]. Three cur-
rent Cochrane reviews on the effectiveness and safety of metamizole for acute postoperative
pain [2], acute renal colic pain [3], and acute primary headaches [4] concluded that metamizole
offers good short-term pain relief. In each of these systematic reviews, however, the number of
included participants was too small and the authors did not conduct a meta-analysis of safety
issues, but they did associate metamizole with somnolence, gastric discomfort and nausea.
Given the still ongoing controversies about the gastrointestinal and cardiovascular safety
profiles of non-steroidal anti-inflammatory drugs (NSAIDs) [10–12], which are among the al-
ternatives to metamizole, a comprehensive systematic review of randomized controlled trials
investigating metamizole use for all indications is needed. We therefore determined whether
metamizole was clinically safe compared to placebo and other commonly used analgesics.
Methods
We used a standard review protocol that was submitted to the funding body prior to the start
of the study.
Literature Search
We searched electronic databases from inception to February 2013, without language restric-
tion, including the Cochrane Controlled Trials Register (CENTRAL) through The Cochrane
Library (http://mrw.interscience.wiley.com/cochrane/), MEDLINE and EMBASE through the
Ovid platform (http://www.ovid.com/) and CINAHL through EBSCOhost. The search algo-
rithm for EMBASE is displayed in S1 Table (it was slightly modified for the other databases).
We searched several clinical trial registries (http://www.controlled-trials.com/;http://www.
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clinicaltrials.gov/, http://www.actr.org.au/, http://www.umin.ac.jp/ctr/) to identify unpublished
trials. We also screened the reference lists of included trials and previous systematic reviews.
Trial selection
We included randomized controlled trials that compared the effects of metamizole in adult pa-
tients, administered in any form and for any indication, to other analgesics or to placebo. Quasi-
randomized trials were not eligible. We selected for inclusion trials that reported any adverse
events. We excluded trials in which metamizole was a co-treatment in more than one arm.
Two review authors independently evaluated all titles and abstracts for eligibility. We resolved
disagreements by consensus or discussion with a third reviewer. We included studies regardless
of length of follow-up or language of publication. If multiple reports described the same trial, we
chose the most recent full-text publication in a peer-reviewed journal as the main report.
Outcome measures
The pre-specified primary end point was any adverse event during the trial period. Secondary
end points were serious adverse events, overall dropouts and dropouts due to adverse events
and serious adverse events. We defined serious adverse events as those that resulted in inpa-
tient hospitalization, persistent or significant disability, congenital abnormality of offspring,
life-threatening events or death [13]. We extracted the number of patients per group who expe-
rienced at least one event before the end of the trial, and categorized and reported them using
the International Classification of Primary Care (ICPC; 2nd edition), which allows for reporting
of both complaints and diagnosis [14].
Data Collection and Quality Assessment
Two authors independently extracted data from the full-text articles. They used a standardized,
piloted extraction form accompanied by a codebook created for this review [15]. Reviewers re-
solved disagreements by consensus or through discussion with a third author.
We extracted data regarding trial size, trial design, trial duration (defined as time from first
application until end of follow-up), indication for pain medication, patient characteristics (sex,
age), treatment regimens (application form, duration and/or frequency of treatment), adverse
events and funding source. We extracted data only from the first period of crossover trials, be-
cause carry-over effects might be present in the later periods. We attempted to contact studies’
corresponding authors to obtain missing information.
Two review authors independently assessed concealment of treatment allocation, blinding
of patients, adequate adverse event assessment and adequacy of analyses. We considered allo-
cation concealment to be adequate if the investigators who selected patients were unable to
guess which treatment patients would be allocated to. We considered patients to be blinded if
the trial was reported as “double blind”. Adverse event assessment was considered adequate if
it was conducted systematically and prospectively. Analyses were considered adequate if all re-
cruited patients were analyzed in the group to which they were originally allocated, regardless
of the treatment received (intention-to-treat principle). See S2 Table for definitions used to
classify trials according to components of methodological quality. Disagreements were resolved
by discussion with a third reviewer and subsequent consensus.
Data Synthesis and Analysis
We conducted separate meta-analyses for each metamizole comparator. We first calculated the
log risk ratio and its standard error for each trial, and then used standard inverse-variance
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random effects meta-analysis to pool these estimates across trials [16]. The pooled estimate
was then exponentiated to report treatment effect estimates as risk ratios (RRs). A RR below 1
indicates that metamizole is a safer intervention than its comparator. We calculated the DerSi-
monian and Laird variance estimate T2 to measure heterogeneity between trials [16]. A T2 of
0.04 was pre-specified to represent low heterogeneity, 0.09 moderate heterogeneity and 0.16
high heterogeneity between trials [17]. We performed stratified analyses of primary and sec-
ondary outcomes according to dose and route of administration. Uni-variable random-effects
meta-regression models were used for tests of interaction between outcomes and these charac-
teristics. We distinguished between single dose and multiple doses, determined the association
of the log risk ratio with daily dose and cumulative dose on a continuous scale, and classified
route of administration as i.m., i.v., or p.o. for this purpose. All p-values are two-sided. Analy-
ses were conducted using STATA, release 11 (Stata-Corp, College Station, Texas).
Results
We identified 8242 references in our literature search, of which 696 were potentially eligible.
Seventy-nine reports describing 79 randomized controlled trials met our inclusion criteria and
were included in the meta-analysis (see PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) flowchart [Fig 1] and checklist [S1 PRISMA Checklist]). Forty-nine
trials were published in English, 12 in Spanish, six in Portuguese, six in German, four in Italian,
and two in Turkish. Trials were conducted in several European and Latin American countries
where metamizole is widely available. All trials were published as full-text journal articles. The
median year of publication was 1995 (range: 1974–2011). A search of trial registries yielded no
ongoing trials.
The average age of participants ranged from 22–64 years (median: 45 years). Women made
up 45.8% of the subjects. A total of 3716 patients received metamizole, 1077 received placebo,
303 received aspirin, 1983 received NSAIDs, 829 received opioids, 362 received paracetamol,
and 156 patients received other pain medications. Very few of the 79 included randomized
controlled trials were conducted in the ambulatory setting. Table 1 describes the clinical char-
acteristics of the trials.
Twenty-four studies (31%) used adequate randomization methods, fourteen studies (18%)
adequately concealed allocation, fifty-five studies (70%) adequately blinded patients and 13
studies (17%) adequately assessed adverse events. Forty-two studies (53%) analyzed all patients
according to the intention-to-treat principle. S3 Table describes the trials’ methodological char-
acteristics. The heterogeneity between the studies was low for most adverse events (T2<0.01).
The data extracted from single studies can be found in S4 Table and S1 Dataset.
Metamizole versus Placebo
Eighty-two adverse events were reported in 619 patients treated with metamizole, compared to
73 adverse events in 520 patients treated with placebo, yielding a RR of 0.96 (95% confidence
interval (CI) 0.73 to 1.25, see Fig 2). Two serious adverse events were reported in the metami-
zole group: one case of leucopenia due to septicemia following aspiration and one case of post-
operative hemorrhage after prostatectomy. In comparison, one serious adverse event was re-
ported in the placebo group, a case of leucopenia due to anastomosis insufficiency [90], yield-
ing a RR of 1.93 (95% CI 0.18 to 20.6). For overall dropouts and dropouts due to adverse
events, 95% CI overlapped the line of no difference. We found no statistically significant differ-
ence in organ-specific safety.
Metamizol and Adverse Events
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Metamizole versus Paracetamol
Twenty-six adverse events were reported in 164 patients treated with metamizole, and 23 in 166
treated with paracetamol, with an RR of 1.08 (95% CI 0.69 to 1.68, see Fig 3). No serious adverse
events were reported, and for overall dropouts and dropouts due to adverse events, 95% CI over-
lapped the line of no difference. Thirteen patients treated with metamizole had cardiovascular
adverse events, compared to two patients treated with paracetamol (RR = 3.48, 95% CI 1.07 to
11.27). All of these patients had hypotension due to intravenous injection of metamizole.
Metamizole versus Aspirin
Twenty adverse events were reported in 227 patients treated with metamizole, and 19 in 149
treated with aspirin, with a RR of 0.80 (95% CI 0.44 to 1.45, see Fig 4). No serious adverse
Fig 1. PRISMA flowchart. The 79 randomized controlled trials [18–95] assessed mainly short-term use of common analgesics. Forty-two trials (53%)
investigated the use of only a single dose of metamizole. In addition, 18 trials (23%) had a maximum treatment duration of only one day, while in 17 trials
treatment lasted from two days up to one week (22%) and only two trials (2%) had a treatment duration of two weeks. Average length of follow-up ranged
from 0.33 to 366 hours (median: 24 hours). Four trials (5%) had sample sizes of at least 100 patients per randomized group (median: 30 patients).
doi:10.1371/journal.pone.0122918.g001
Metamizol and Adverse Events
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Table 1. Clinical characteristics of the trials.
Trial year n1 Indication Comparison form of application2 Treatment
duration (days)
Ajgaonkar 1985 42/46 Fever Placebo p.o. single dose
Arnau 1991 217/ 116 Renal colic Diclofenac, Pethidine i.m. single dose
Atalay 1995 14/38 Post-OP Fentanyl, Morphine i.m. / epidural catheter single dose
Babej-Dölle 1994 88/ 172 Diclofenac, Placebo i.m. 2
Bagan 1998 40/80 Post-OP Dexketoprofen p.o. 3
Bigal 2002 74/60 Migraine Placebo i.v. single dose
Bilgin 2003 25/25 Post-OP Bupivacaine extrapleural catheter 3
Blendinger 1980 7/10 Post-OP ASS i.v. single dose
Bloch 1985 68/65 Post-OP Pethidine i.m. 2
Boraks 1987 39/ 120 Post-OP Flurbiprofen, Placebo p.o. single dose
Braun 1999 76/79 Post-OP Placebo i.v. 0.042
Brodner 2011 49/ 147 Post-OP Parecoxib, PCM, Placebo i.v. 2
Castro 2000 30/68 Post-OP Ketorolac, Tramadol i.v. 1
Castro Gonzales 1986 28/58 Post-OP Dexketoprofen, Ibuprofen p.o. 1.667
Cruz 2002 30/30 Fever Propacetamol i.v. single dose
De Miguel Rivero 1997 35/72 Post-OP Ibuprofen, Placebo i.m. / p.o. single dose
Diaz-Chavez 2009 47/48 Post-OP Ketorolac i.v. / p.o. 1
Dos Santos Pereira 1986 28/57 Post-OP Acetaminophen, Placebo p.o. single dose
Duarte Souza 2007 18/16 Cancer Placebo p.o. 2
Fernandes Filho 2006 12/15 Migraine MCP i.v. single dose
Ferrario 1984 14/14 Post-OP ASS i.m. / i.v. single dose
Gomes-Marquez 2004 25/25 Post-OP Parecoxib i.v. single dose
Gonzalez-Garcia 1994 unclear Post-OP Ketorolac p.o. single dose
Grundmann 2006 20/60 Post-OP Parecoxib, PCM, Placebo i.v. single dose
Guberti 1982 14/14 Post-OP Nefopam i.v. 4
Hernandez Llenas 1997 15/15 Post-OP Diclofenac i.v. 0.336
Herrera Barroso 1982 30/60 Post-OP Zomepirac, Placebo p.o. single dose
Ibarra-Ibarra 1993 48/49 Post-OP Ketorolac i.m. single dose
Jage 1990 40/40 Post-OP Placebo i.v. 1
Jovic 2008 30/30 Post-OP Ketoprofen i.v. 5
Kampe 2006 20/20 Post-OP PCM i.v. 1
Karaman 2010 30/60 Post-OP Dexketoprofen, PCM i.v. 1
Kemal 2007 20/20 Post-OP Lornoxicam i.v. 1
Knüsel 1982 40/40 Osteoarthritis Zomepirac p.o. 14
Krymchantowski 2008 15/15 Migraine Lysin Clonixinate i.v. single dose
Landwehr 2005 13/12 Post-OP PCM i.v. 1.021
Lehmann 2001 40/40 Post-OP Placebo i.v. 1
Lehtonen 1983 45/124 Renal colic Indomethacin, Pethidine i.v. single dose
Marin-Bertolin 1997 46/46 Post-OP Ketorolac i.m. 2
Martin-Duce 1997 187/48 Post-OP Diclofenac i.m. / i.v. single dose
Martinez-Martin 2001 204/207 Migraine ASS p.o. single dose
Mateu 1992 38/80 Post-Trauma ASS, PCM p.o. single dose
Mehta 1986 91/163 Post-OP ASS, Placebo p.o. single dose
Monso 1996 37/67 Shivering Pethidine, Placebo i.v. single dose
Muriel 1993 87/41 Renal colic Diclofenac i.v. single dose
Muriel-Villoria 1995 239/54 Renal colic Diclofenac i.m. single dose
(Continued)
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events were reported, and for overall dropouts and dropouts due to adverse events, 95% CI
overlapped the line of no difference. We found no statistically significant difference in organ-
specific safety.
Metamizole versus NSAIDs
Two hundred and thirteen adverse events were reported in 858 patients treated with metamizole,
compared to 295 adverse events in 1086 treated with NSAIDs, yielding a RR of 0.91 (95% CI 0.79
to 1.05, see Fig 5). Nine serious adverse events were reported in the metamizole group and 24
Table 1. (Continued)
Trial year n1 Indication Comparison form of application2 Treatment
duration (days)
Ocampo Flores 1986 15/30 Post-OP Ibuprofen, Dextropropoxifene p.o. 1.667
Pardo 1984 30/60 Renal colic Ceruletide, Placebo i.v. single dose
Patel 1980 51/49 Post-OP Pethidine i.m. single dose
Pavlik 2004 32/32 Renal colic Cizolirtin i.v. single dose
Peiró 2008 8/8 Pancreatitis Morphine i.v. / s.c. 2
Pernia 2000 30/37 Post-OP Propacetamol i.v. 1
Pinto 1984 27/29 Post-OP Acetaminophen p.o. single dose
Planas 1998 147/106 Post-OP Ibuprofen, Placebo p.o. single dose
Prada 1974 20/40 Post-OP Pentazocine supp. single dose
Primus 1989 30/30 Renal colic Tramadol i.v. single dose
Rawal 2001 40/80 Post-OP Tramadol p.o. 2
Rejman 1984 25/25 Biliary colic Indomethacin i.v. single dose
Reyes 1988 25/25 Post-OP Diclofenac i.v. single dose
Reyes-Armijo 1974 15/15 Migraine Vitamin B1, B6 p.o. 14
Rodriguez 1994 79/42 Cancer Morphine p.o. 7
Rubinstein 1986 30/60 Post-OP Acetaminophen p.o. single dose
Sanchez-Carpena 2003 108/225 Renal colic Dexketoprofen i.m. single dose
Sanchez-Carpena 2007 103/205 Renal colic Dexketoprofen i.v. single dose
Saray 2001 80/80 Post-OP Diclofenac i.m. 2
Savoca 1985 15/15 Post-OP Imidazol-2-Hydroxybenzoat p.o. 1
Schmieder 1993 25/49 Biliary colic Butylscopolamin i.v. single dose
Sener 2008 40/160 Post-OP Diclofenac, Ketoprofen, Lornoxicam, Placebo i.m. 0.667
Spacek 2003 30/30 Post-OP Placebo i.v. 1
Stankov 1994 36/68 Renal colic Butylscopolamin i.v. single dose
Stankov 1995 51/49 Post-OP Tramadol i.v. single dose
Steffen 1997 20/20 Post-OP Tramadol i.v. 0.5
Striebel 1992 30/30 Post-OP Placebo i.v. 0.167
Tempel 1996 54/52 Post-OP Placebo i.v. 0.667
Tonolli Jacob 1986 33/66 Post-Trauma Diclofenac, Placebo i.m. single dose
Torres 1993 50/100 Post-OP Buprenorphin, Morphine i.v. 0.072
Torres 2001 73/78 Post-OP Tramadol i.v. 1
Uzun 2010 23/20 Post-OP Placebo i.v. single dose
Vargha von Szeged 1986 30/30 Migraine Suprofen p.o. 5
1: n (patients) Metamizole / n (patients) comparisons.
2: i.m.: intramuscular, i.v.: intravenous, p.o.: per os, supp: suppository, s.c.: subcutaneous.
doi:10.1371/journal.pone.0122918.t001
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serious adverse events were reported in the NSAID group. With the exception of two postopera-
tive hemorrhages after abdominoplasty described in participants allocated to an NSAID in one
trial [56], the majority of the remaining 22 serious adverse events in two trials by the same re-
search group were described as ‘cases of recurrence of renal pain that led to hospitalization
[80,81]. For overall dropouts, dropouts due to adverse events and drop-outs due to serious ad-
verse events, CI overlapped the line of no difference. One dropout due to serious adverse events
was a post-operative hemorrhage in the NSAID group [56]. Forty-nine patients treated with
metamizole had neurological adverse events compared to 87 treated with NSAIDs (RR 0.75, 95%
CI 0.57 to 0.99). The most common reason was headache or unspecific vertigo and dizziness.
Metamizole versus Opioids
Ninety adverse events were reported in 279 patients treated with metamizole, compared to 115
adverse events in 290 treated with opioids, yielding a RR of 0.79 (95% CI 0.79 to 0.96, see Fig
6). No serious adverse events were reported, and for overall dropouts and dropouts due to
Fig 2. Forest plot—Metamizole versus Placebo.Categories according to the International Classification of Primary Care (see Methods section and [13]).
Results from single studies are of limited interpretability but are displayed for the sake of completeness. RR = risk ratio. AE = adverse events. SAE = serious
adverse events.
doi:10.1371/journal.pone.0122918.g002
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adverse events, CI overlapped the line of no difference. Ten patients in the metamizole group
reported pain at the injection site, compared to none in the opioid group (RR = 11.8, 95% CI
2.2 to 63.7). Twelve patients in the metamizole group reported vomiting compared to 54 in the
opioid group (RR = 0.48, 95% CI 0.26 to 0.86), while five metamizole patients compared to 22
taking opioids reported neurological signs, most commonly vertigo, dizziness or headache
(RR = 0.29, 95% CI 0.12 to 0.68). Unspecific and general complaints such as sweating, tired-
ness, somnolence, shaking and fever were less common in the metamizole group than in the
opioid group (15 versus 57 events, RR = 0.50, 95% CI 0.27 to 0.92).
Tests of interaction indicated no evidence of an association between outcomes and dose or
route of administration. Results of these interaction tests must be carefully interpreted given
their low power, however.
Fig 3. Forest plot—Metamizole versus Paracetamol. Categories according to the International Classification of Primary Care (see Methods section and
[13]). Results from single studies are of limited interpretability but are displayed for the sake of completeness. RR = risk ratio. AE = adverse events.
SAE = serious adverse events.
doi:10.1371/journal.pone.0122918.g003
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Serious adverse events, agranulocytosis and death
None of the trials reported agranulocytosis or withdrawals due to death. In addition, the trial-
ists did not attribute any of the above-mentioned serious adverse events to metamizole.
Discussion
In our meta-analysis of randomized controlled trials that compared the safety of metamizole to
placebo and other analgesics, there was no difference in adverse events between metamizole
and placebo, paracetamol, aspirin, or NSAIDs, and fewer adverse events compared to opioids.
These 79 trials, which included almost 4000 patients with short-term metamizole use of less
than two weeks, reported few serious adverse events, with no difference between metamizole
and the comparators, and no cases of agranulocytosis.
Our approach to studying organ-specific differences identified several statistically signifi-
cant differences in the frequency of adverse events, most of which seemed clinically plausible.
Fig 4. Forest plot—Metamizole versus Aspirin.Categories according to the International Classification of Primary Care (see Methods section and [13]).
Results from single studies are of limited interpretability but are displayed for the sake of completeness. RR = risk ratio. AE = adverse events. SAE = serious
adverse events.
doi:10.1371/journal.pone.0122918.g004
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First, compared to paracetamol, patients treated with metamizole had a significantly higher
rate of adverse cardiovascular events, most commonly hypotension. Most of the trials in which
these adverse events were reported used intravenously administered metamizole, which can de-
crease systolic blood pressure [96]. Second, compared with NSAIDs, metamizole was less likely
to be associated with neurological adverse events such as headache, vertigo or dizziness. This
finding is consistent with a standard textbook on drug side effects1, which describes neurologi-
cal adverse events as “never” being caused by metamizole. Third, compared to opioids, meta-
mizole was less frequently associated with neurological and unspecific adverse events, most
commonly vertigo, dizziness, tiredness, sedation and CNS depression. Opioids and metamizole
have different modes of action, and the described adverse events are well documented for opi-
oids but not for metamizole [1]. However, it is not clear why metamizole caused more pain at
the injection site compared to opioids.
Our systematic review was strengthened by the highly sensitive search strategy employed.
We captured as many relevant studies as possible by including trials published in all languages,
Fig 5. Forest plot—Metamizole versus NSAIDs.Categories according to the International Classification of Primary Care (see Methods section and [13]).
Results from single studies are of limited interpretability but are displayed for the sake of completeness. RR = risk ratio. AE = adverse events. SAE = serious
adverse events.
doi:10.1371/journal.pone.0122918.g005
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contacting the authors of studies published in the last 12 years and performing the additional
reference list search. Because we included studies that examined metamizole for all indications,
we were able to analyze 79 studies, while the three Cochrane reviews, which assessed clinical ef-
fectiveness only in postoperative pain, renal colic pain and acute primary headaches, analyzed
15 [2], 11 [3] and four [4] studies, respectively. We also included more patients; our study eval-
uated 8426 patients, while the Cochrane reviews evaluated 1436 [2], 1053 [3] and 636 [4]. Our
search strategy enabled us to conduct a safety analysis and identify serious adverse events,
which the Cochrane reviews were not able to do.
The generalizability of our results is limited by the methodological characteristics of the
studies we included. Studies did not consistently assess adverse events, and only 17% of studies
had a low risk of bias. Adverse events were also reported differently between trials, which fur-
ther limits the validity of our results [97]. The trials we included were underpowered to demon-
strate differences in drug safety. Few trials were conducted in ambulatory settings, limiting the
Fig 6. Forest plot—Metamizole versus Opioids.Categories according to the International Classification of Primary Care (see Methods section and [13]).
Results from single studies are of limited interpretability but are displayed for the sake of completeness. RR = risk ratio. AE = adverse events. SAE = serious
adverse events.
doi:10.1371/journal.pone.0122918.g006
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generalizability of our results for community usage. The included trials also had very short fol-
low-up periods, so it is impossible to draw conclusions about intermediate- and long-term ad-
verse events from the available evidence. The small sample size and short-term follow-up of
included trials means that the number of accumulated events (see Figs 2–6) is small for nearly
all safety outcomes, which renders our results imprecise and our meta-analyses unreliable as
previously discussed by Flather et al [98]. Because many of the included studies were conducted
before mandatory trial registers were introduced, we cannot rule out publication bias; we did,
however, search different trial registers to minimize the probability of bias.
We only considered the safety aspects of metamizole and did not evaluate efficacy, which
the above-mentioned Cochrane reviews found was similar to that of other widely used analge-
sics for three different indications: postoperative pain, renal colic pain and acute primary head-
aches [2–4]. Given these findings, an analgesic should be chosen based on its safety profile.
Metamizole was associated with fewer adverse events than opioids and had a better neurologi-
cal side effect profile than NSAIDs. However, we found no differences regarding the most re-
cently discussed end points of gastrointestinal and cardiovascular safety [10–12]. This
contrasts with a comparative overall safety analysis of four different analgesics (aspirin, diclofe-
nac, acetaminophen and metamizole) based on epidemiological studies published between
1970 and 1995 [7]. In this analysis, Andrade et al included data on short-term (one-week) use
of the analgesics and estimated the excess mortality due to agranulocytosis, aplastic anemia,
anaphylaxis and serious upper gastrointestinal complications. The authors found an excess
mortality for metamizole of 25 per 100 million compared to 592 per million for diclofenac, 185
for aspirin and 20 for paracetamol. Serious upper gastrointestinal complications largely ac-
counted for the excess mortality associated with diclofenac and aspirin [7].
None of the included randomized trials reported agranulocytosis, which is a rare but very
harmful adverse event associated with metamizole [8]. There are huge variations in its estimat-
ed incidence [99], ranging from 1 case per 1431 prescriptions in a Swedish study [100] to 9
cases per million per year in the International Agranulocytosis and Aplastic Anemia Study
[101]. Even if we assume the Swedish estimate to be correct, the number and size of the trials
included in our review would be too small to yield more than only a few agranulocytosis cases.
A systematic review of observational studies investigating the frequency of metamizole-associ-
ated agranulocytosis is currently under preparation by our working group.
Conclusion
For short-term use in the hospital setting, such as to treat renal colic or postoperative pain,
metamizole seems to be a safe choice when compared to other widely used analgesics. There is
very limited information available on the intermediate- and long-term safety of metamizole.
High-quality, adequately sized trials assessing metamizole-associated adverse events in the am-
bulatory setting are needed.
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